OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo

OSCCAR：一种新型的、基于人群的前瞻性炎症 Bo 起始队列

• 批准号: 7481082
• 负责人: BRUCE E SANDS
• 金额: $ 13.34万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7481082
• 关键词: ABCB1 gene; Adverse effects; Affect; Alleles; Bacteriology; Biological; Biological Markers; Blood; Canada; Chronic; Clinical; Colitis; Condition; Country; Crohn' s disease; Data; Descriptive Epidemiology; Development; Diagnosis; Disease; Disease Progression; Disease susceptibility; Education; Environmental Risk Factor; Feces; Gastroenterologist; Gastrointestinal tract structure; Gene Expression; General Population; Genetic; Goals; Immune; Immune system; Incidence; Individual; Inflammatory; Inflammatory Bowel Diseases; Intestines; Marker Discovery; Methods; Modeling; Morbidity - disease rate; Natural History; Newly Diagnosed; Nurses; Operative Surgical Procedures; Outcome; Patients; Population; Procedures; Prognostic Marker; Proteomics; Race; Rate; Relapse; Reporting; Rhode Island; Risk; Risk Factors; Screening procedure; Specimen; Steroid Resistance; System; Technology; Therapeutic immunosuppression; Time; Training; Ulcerative Colitis; United States; Visit; Western Europe; base; cohort; disability; health care delivery; high throughput technology; insight; metabolomics; novel; outcome forecast; prevent; prospective; racial and ethnic; trend

DESCRIPTION (provided by applicant): Crohn's disease (CD) and ulcerative colitis (UC) are chronic remitting and relapsing inflammatory disorders of the gastrointestinal tract that are collectively called the inflammatory bowel diseases (IBD). While increasingly effective therapies have come into use, these diseases continue to result in significant short and long term morbidity, surgery, and disability. IBD is believed to result from dysregulation of the gut's immune system occurring in genetically predisposed individuals who are exposed to one or more unknown environmental triggers. Trends of rising incidence rates reported in different regions around the world strongly implicate environmental factors. Furthermore, genetic and environmental factors affecting the rate of disease progression and prognosis are poorly understood. However, the lack of well-defined, prospectively evaluated inception cohorts is a critical barrier to developing prognostic markers and models of disease progression in IBD. Consequently, a prospectively accrued inception cohort of IBD patients is needed. We propose to create a prospective, population-based inception cohort of CD and UC patients in the state of Rhode Island. In addition to defining the incidence rates and contemporary natural history of IBD in the US, we intend to collect a variety of biological specimens close to the time of diagnosis. We believe that analysis of these specimens using cutting edge screening technologies (including gene expression arrays, proteomics, metabolomics, and stool bacteriology by non-classical methods) will yield invaluable insights into environmental and genetic factors affecting disease susceptibility and prognosis. The ultimate goal in creating this inception cohort is to facilitate the development of prognostic markers in CD and UC. We intend to identify newly diagnosed cases of Crohn's disease, ulcerative colitis and indeterminate colitis, which are chronic intestinal conditions, in the state of Rhode Island in order to project how common these diseases occur in the United States as a whole. We will follow these patients over time to determine the progression of their disease and to compare this to markers in the blood as a way of developing a system to predict the individual course of disease.

描述（由申请人提供）：克罗恩病（CD）和溃疡性结肠炎（UC）是慢性恢复和复发性的胃肠道炎症性疾病，这些疾病统称为炎症性肠病（IBD）。尽管已经使用了越来越有效的疗法，但这些疾病继续导致显着的短期发病率，手术和残疾。据信，IBD是由于暴露于一个或多个未知的环境触发器的遗传性易感个体中发生的肠道免疫系统失调而引起的。在世界各地报告的发病率上升率上升趋势强烈暗示环境因素。此外，对影响疾病进展和预后率的遗传和环境因素知之甚少。然而，缺乏明确的，前瞻性评估的成立队列是发展IBD中预后标记和疾病进展模型的关键障碍。因此，需要前瞻性的IBD患者组成。我们建议在罗德岛州建立一个基于人群的cd和UC患者的前瞻性成立队列。除了定义美国IBD的发病率和当代自然历史外，我们还打算收集接近诊断时间的各种生物标本。我们认为，使用尖端筛选技术（包括基因表达阵列，蛋白质组学，代谢组学和粪便细菌学）对这些标本的分析将产生对影响疾病易感性和预后的环境和遗传因素的宝贵见解。创建这种开始队列的最终目标是促进CD和UC中预后标记的发展。我们打算在罗德岛州确定新诊断的克罗恩病，溃疡性结肠炎和不确定的结肠炎，这些病例是慢性肠道疾病，以预测这些疾病在整个美国如何发生。随着时间的流逝，我们将跟随这些患者，以确定其疾病的进展，并将其与血液中的标记相提并论，以此作为开发系统以预测个体疾病过程的方式。